Comparative Pharmacology
Head-to-head clinical analysis: ALFUZOSIN HYDROCHLORIDE versus DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALFUZOSIN HYDROCHLORIDE versus DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE.
ALFUZOSIN HYDROCHLORIDE vs DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective antagonist of postsynaptic alpha-1 adrenergic receptors in the prostate, bladder base, and prostatic urethra, leading to smooth muscle relaxation and improved urine flow.
Dutasteride inhibits both type 1 and type 2 isoforms of 5α-reductase, preventing conversion of testosterone to dihydrotestosterone (DHT), reducing prostate volume. Tamsulosin is a selective antagonist of alpha-1A and alpha-1D adrenoceptors, relaxing smooth muscle in the prostate and bladder neck.
10 mg orally once daily immediately after the same meal each day. Extended-release tablet.
One capsule (dutasteride 0.5 mg / tamsulosin hydrochloride 0.4 mg) orally once daily, approximately 30 minutes after the same meal each day.
None Documented
None Documented
Terminal elimination half-life: 5-7 hours in patients with benign prostatic hyperplasia; 7-10 hours in elderly; prolonged in hepatic impairment.
Dutasteride: Terminal half-life ~5 weeks (3-7 weeks), allowing once-daily dosing; steady-state reached at 3-6 months. Tamsulosin: Terminal half-life ~9-13 hours in healthy subjects, prolonged in elderly (up to 16-19 hours).
Primarily hepatic metabolism (CYP3A4); 11% renal excretion as unchanged drug; 69% fecal elimination (biliary), 24% urinary (total).
Dutasteride: 40% as metabolites in feces (mainly via bile), 5% in urine. Tamsulosin: 76% in urine as unchanged drug and metabolites, 24% in feces.
Category C
Category A/B
Alpha-1 Blocker
Alpha-1 Blocker